|Bid||175.00 x 900|
|Ask||180.99 x 1100|
|Day's Range||172.14 - 180.00|
|52 Week Range||123.00 - 197.86|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||52.44|
|Earnings Date||Apr 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||191.60|
IRVINE, Calif., April 18, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the completion of its acquisition of CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring. Edwards announced in February that it had signed an agreement to acquire CASMED. Under the terms of the agreement, Edwards paid $2.45 in cash for each common share of CASMED, which equates to an equity value of approximately $100 million.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (NYSE:EW) is a top holding because we think there continues to be a multiyear runway for excellent top-line and bottom-line growth. Adjusted sales during the Company's fourth quarter grew +10%, driven by a +11% increase in transcatheter heart valve (THV) therapies. Edwards also released positive results of a highly anticipated trial that evaluated the performance of transcatheter aortic valve replacement (TAVR) in a previously unserved population.
Top first quarter performance detractors include Qualcomm, Berkshire Hathaway, Booking Holdings, Alphabet Class C, and Starbucks, plus Charles Schwab and C.H. Robinson. During the quarter we sold Qualcomm and trimmed positions in Ross Stores, Old Dominion Freight Line, and Charles Schwab.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
IRVINE, Calif. , April 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Edwards LifesciencesRead More...
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
High-margin stocks with 'pricing power' in their markets are well positioned for more gains ahead, according to Goldman Sachs. This group of 50 stocks has posted stunning performance in the past year compared to low-margin stocks, and may outperform in the upcoming period as rising costs continue to pressure U.S. corporations, says Goldman in its latest US Thematic Views report. "Growing margin pressures have driven the outperformance of stocks with high pricing power," the firm says.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
In addition, these stocks received very high ratings from GuruFocus for financial strength as well as profitability and growth. Warning! GuruFocus has detected 5 Warning Sign with EW. Edwards Lifesciences Corp. (EW) has gained 9% over the last week, 8% over the past month, 25% so far this year, 35% over the last 52 weeks and 122% over the past three years through March 18.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...
Edwards stock jumped to a record high Monday after the medtech company's TAVR heart-valve replacement outperformed surgery in a yearlong clinical study. Medtronic and Boston stocks sank.
The Fed's two-day policy meeting begins on Tuesday, where the central bank is widely expected to keep interest rates steady and reiterate its "patient" approach to monetary policy. Investors will be looking for whether the Fed's dot plot, which shows individual committee members' rate views for the coming three years, aligns with the patient approach.